Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

ConclusionsThis preclinical proof-of-principle study is first to support the therapeutic efficacy of cancer immunotherapy with syngeneic dead tumor cell antigen-loaded mouse cDC1s, the equivalents of the human dendritic cell subset that correlates with beneficial prognosis of cancer patients. Our data pave the way for translation of cDC1-based cancer treatments into the clinic when isolation of natural human cDC1s becomes feasible.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research